# Frequent cannabis users wake with higher cortisol levels, study finds > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/frequent-cannabis-users-wake-with-higher-cortisol-levels-study-finds/ > **Published:** 2026-07-22T17:11:07-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:03:09-04:00 > **Clinical Summary:** Study links chronic cannabis use to elevated morning cortisol. Learn what this HPA axis finding means for long-term users and clinical monitoring. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. SleepAnxietyMental HealthTHCResearchSafetyNeurology Why This Matters Clinicians should recognize that while patients report using [cannabis for anxiety](https://cedclinic.com/medical-cannabis-safety-facts/) and stress relief, frequent use may dysregulate the hypothalamic-pituitary-adreatic (HPA) axis, resulting in elevated morning cortisol and potentially worsening long-term stress resilience. This finding suggests that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) counseling should include discussion of paradoxical effects on stress physiology and the risk that chronic use undermines the body’s natural stress-response mechanisms. Patients seeking cannabis for [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) need alternative or complementary evidence-based treatments such as cognitive behavioral therapy or other pharmacological options that don’t disrupt normal cortisol dynamics. Clinical Summary A prospective study examining frequent cannabis users found elevated morning cortisol levels compared to non-users, suggesting that chronic cannabis consumption may dysregulate the hypothalamic-pituitary-adrenal axis despite users’ perception of stress relief. While acute [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may produce anxiolytic effects through [cannabinoid receptor signaling](https://cedclinic.com/cannabis-brain-volume-study-cognitive-benefits/), the findings indicate that regular use could lead to maladaptive changes in endogenous cortisol production and stress responsiveness over time. This has important implications for patients using cannabis therapeutically for anxiety or stress-related conditions, as chronic elevation of morning cortisol is associated with metabolic dysfunction, immune suppression, and potential exacerbation of psychiatric symptoms. Clinicians should counsel frequent cannabis users about the paradoxical risk that long-term use may ultimately worsen stress physiology, particularly in patients with baseline cortisol dysregulation or stress-sensitive conditions. These findings suggest that cannabis may be more appropriate for acute situational anxiety rather than as a chronic maintenance therapy for stress management. Practitioners should monitor HPA axis function in chronic users and consider alternative evidence-based treatments for long-term [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/). Dr. Caplan’s Take “This observational finding is intriguing because it suggests a potential disconnect between cannabis’s acute anxiolytic effects and its longer-term impact on the hypothalamic-pituitary-adrenal axis, but we need to be cautious about interpreting causation from cross-sectional data—elevated morning cortisol could reflect the underlying stress that drives frequent use rather than cannabis causing it, and replication in controlled longitudinal studies will be essential before we counsel patients about this mechanism.” Clinical Perspective 💊 While acute [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may temporarily reduce perceived stress through anxiolytic effects, this emerging evidence suggesting elevated morning cortisol in frequent users warrants clinical attention as a potential indicator of dysregulated hypothalamic-pituitary-adrenal axis function. The cross-sectional nature of such studies limits causal inference—elevated cortisol could reflect underlying stress driving heavier use rather than cannabis causing the elevation—and confounders including sleep quality, withdrawal symptoms, and baseline [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) complicate interpretation. Practitioners should consider asking patients about cannabis frequency and timing of use when evaluating patients with stress-related symptoms, unexplained fatigue, or metabolic concerns, while recognizing that individual responses vary considerably. Counseling frequent cannabis users about potential long-term effects on stress physiology may support more informed decision-making, particularly for those using cannabis specifically for [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/), since paradoxical HPA-axis sensitization could undermine therapeutic 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Frequent%20cannabis%20users%20wake%20with%20higher%20cortisol%20levels%2C%20study%20finds%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71152)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71152)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Frequent%20cannabis%20users%20wake%20with%20higher%20cortisol%20levels%2C%20study%20finds%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71152)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://medicalxpress.com/news/2026-07-frequent-cannabis-users-higher-cortisol.html](https://medicalxpress.com/news/2026-07-frequent-cannabis-users-higher-cortisol.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).